Chapter title |
Activating Human Adipose Tissue with the β3-Adrenergic Agonist Mirabegron.
|
---|---|
Book title |
Brown Adipose Tissue
|
Published in |
Methods in molecular biology, January 2022
|
DOI | 10.1007/978-1-0716-2087-8_5 |
Pubmed ID | |
Book ISBNs |
978-1-07-162086-1, 978-1-07-162087-8
|
Authors |
Chen, Kong Y, Brychta, Robert J, Israni, Nikita S, Jiang, Alex, Lea, Hannah J, Lentz, Taylor N, Pierce, Anne E, Cypess, Aaron M, Chen, Kong Y., Brychta, Robert J., Israni, Nikita S., Lea, Hannah J., Lentz, Taylor N., Pierce, Anne E., Cypess, Aaron M., Kong Y. Chen, Robert J. Brychta, Nikita S. Israni, Alex Jiang, Hannah J. Lea, Taylor N. Lentz, Anne E. Pierce, Aaron M. Cypess |
Abstract |
An appealing strategy for treatment of metabolic disease in humans is activation of brown adipose tissue (BAT), a thermogenic organ best visualized through 18F-FDG PET/CT. BAT has been activated to varying degrees by mild cold exposure. However, this approach can cause undesirable stress, and there remains no consensus protocol. Here, we describe standardized methods for both acute and chronic activation of BAT using the orally administered β3-adrenergic receptor (AR) agonist, mirabegron. Acute pharmacological stimulation has enabled quantification of whole-body BAT volume and metabolic activity using PET/CT imaging, and chronic stimulation increases these properties of BAT over time. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 2 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 8 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 5 | 63% |
Student > Master | 1 | 13% |
Unknown | 2 | 25% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 2 | 25% |
Medicine and Dentistry | 2 | 25% |
Sports and Recreations | 1 | 13% |
Unknown | 3 | 38% |